Regeneron Pharmaceuticals Inc (REGN)
896.26
+2.76
(+0.31%)
USD |
NASDAQ |
Apr 19, 16:00
896.26
0.00 (0.00%)
After-Hours: 18:46
Regeneron Pharmaceuticals Cash from Operations (TTM): 4.594B for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 4.594B |
September 30, 2023 | 5.224B |
June 30, 2023 | 4.739B |
March 31, 2023 | 4.281B |
December 31, 2022 | 5.015B |
September 30, 2022 | 5.668B |
June 30, 2022 | 8.452B |
March 31, 2022 | 8.514B |
December 31, 2021 | 7.081B |
September 30, 2021 | 5.940B |
June 30, 2021 | 2.272B |
March 31, 2021 | 2.589B |
December 31, 2020 | 2.618B |
September 30, 2020 | 2.174B |
June 30, 2020 | 2.986B |
March 31, 2020 | 2.231B |
December 31, 2019 | 2.43B |
September 30, 2019 | 2.371B |
June 30, 2019 | 2.267B |
March 31, 2019 | 2.473B |
December 31, 2018 | 2.195B |
September 30, 2018 | 2.033B |
June 30, 2018 | 1.995B |
March 31, 2018 | 1.570B |
December 31, 2017 | 1.307B |
Date | Value |
---|---|
September 30, 2017 | 1.131B |
June 30, 2017 | 1.367B |
March 31, 2017 | 1.797B |
December 31, 2016 | 1.486B |
September 30, 2016 | 1.377B |
June 30, 2016 | 1.619B |
March 31, 2016 | 1.477B |
December 31, 2015 | 1.331B |
September 30, 2015 | 1.247B |
June 30, 2015 | 518.60M |
March 31, 2015 | 597.18M |
December 31, 2014 | 752.44M |
September 30, 2014 | 835.99M |
June 30, 2014 | 764.12M |
March 31, 2014 | 555.88M |
December 31, 2013 | 588.60M |
September 30, 2013 | 400.05M |
June 30, 2013 | 305.22M |
March 31, 2013 | 98.67M |
December 31, 2012 | -74.62M |
September 30, 2012 | -218.12M |
June 30, 2012 | -262.47M |
March 31, 2012 | -218.14M |
December 31, 2011 | -141.68M |
September 30, 2011 | -132.22M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
2.174B
Minimum
Sep 2020
8.514B
Maximum
Mar 2022
4.287B
Average
4.281B
Median
Mar 2023
Cash from Operations (TTM) Benchmarks
Vertex Pharmaceuticals Inc | 3.537B |
Eli Lilly and Co | 4.240B |
CytomX Therapeutics Inc | -56.04M |
Pfizer Inc | 8.70B |
Puma Biotechnology Inc | 27.01M |